cyc 202 has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
| De Rose, V; Ghigo, A; Prono, G; Riccardi, E | 1 |
1 review(s) available for cyc 202 and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Cannabinoids; COVID-19; COVID-19 Drug Treatment; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Eicosanoids; Humans; Inflammation; Protein Kinase Inhibitors; Roscovitine; Signal Transduction; Thymalfasin | 2021 |
1 other study(ies) available for cyc 202 and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |